T-Knife Therapeutics

Biotechnology

T-Knife Therapeutics is a private biotechnology company. It has raised $110 million across 1 recorded round; the latest was an $110 million Series B in Aug 2021.

PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$110.0M
Last round
Later Stage VC (Series B)
Aug 2021
No prints on record

No secondary trades in T-Knife Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Pro
The prices on T-Knife Therapeutics
  • ·18 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Where T-Knife Therapeutics prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of T-Knife Therapeutics stock.